Targeting the glycosphingolipids metabolism in H3K27M-mutant DMG with CNS-penetrant glucosylceramide synthase inhibitors may accelerate the access of H3K27M-mutant DMG patients to new therapies for this highly aggressive tumor. Here, UGCG is linked to neoplasm.